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Abstract. Placenta growth factor (PLGF) is a member of the
vascular endothelial growth factor (VEGF) family, a group of
angiogenic growth factors. Recently, isoforms have been
identified. This study examined PLGF-1, PGF-2 and its
receptor neuropilin-1 levels in human breast cancer in relation
to patient's clinical parameters and how changes in expression
may be linked to prognosis of the disease. PLGF-1, PGF-2
and neuropilin-1 transcript expression and distribution were
examined quantitatively using real-time quantitative poly-
merase chain reaction (Q-PCR) on a cohort of human breast
cancer (n=114) and background breast tissue (n=30) with a
10-year follow-up. Protein expression was assessed by an
immunohistochemical method. We demonstrate that PLGF-1
transcript levels were significantly elevated when comparing
tumours from patients with poor outcome and patients who
remained disease-free (P=0.03), indicating a potential
prognostic value. Immunohistochemistry demonstrated a
marked increased in PGF-2 expression in tumour section
compared with normal tissues (P<0.05). PGF-2 transcripts,
showed little change in expression between tumour and
background. High levels of PLGF-1 and PGF-2 were seen in
ERß-negative breast tumour tissues. Neuropilin transcript
was below detection in substantial portion of the samples and
was more frequently detected in high grade tumours (P=0.008
vs. low grade) and in tumours from patients who died of breast
cancer (P<0.001 vs. those who remained disease-free). Our
study shows that PLGF isoforms PLGF-1 and PGF-2 and
indeed their receptor neuopilin, have an aberrant pattern of
expression and that high levels of the PLGF-1 and neuropilin
are linked to a poor prognosis.
Introduction
Angiogenesis, the process involving growth of new blood
vessels, is an essential component of the metastatic pathway.
These vessels provide the principal route by which tumour cells
exit the primary tumour site and enter the circulation, without
which the tumour would fail to develop. Tumour angiogenesis
is regulated by pro-angiogenic factors [including FGF
(fibroblast growth factor) and VEGF (vascular endothelial
growth factor)] and anti-angiogenic factors such as thrombo-
spondin-1 (TSP-1), endostastin and angiostastin (1). Among
the growth factors implicated in tumour angiogenesis, VEGF
appears to be a major contributor in angiogenesis in solid
tumours. Different VEGF family member appears to have a
specific function: VEGF-C and VEGF-D both are primarily
lymphangiogenic factors, while VEGF and VEGF-B are
primarily angiogenic (2). In addition, VEGF directly promotes
proliferation and/or migration of VEGF receptor-expressing
tumour cells and they are also involved in mobilization of
endothelial and haematopoietic stem cells (HSCs) from the
bone marrow and their recruitment at the tumour site where
they contribute to tumour angiogenesis (3).
Placenta growth factor, PGF, is a member of the VEGF
family which is mainly expressed in the placenta and within
the placenta the major cellular source is trophoblast (4). It is
also found expressed in vascular endothelium, umbilical vein
endothelial cells, the eye, uterine natural killer cells and
dentine matrix. It is a homodimeric glyprotein that displays
homology with VEGF, sharing 53% similarity in its overall
amino acid residues. Human PGF gene has been mapped to
chromosome 14q24. PGF-coding sequence is encoded by
seven exons spanning an 800-kb long DNA interval (5). As a
result of alternative splicing the primary PGF transcript, PGF
has at least three isoforms, PLGF-1, PGF-2, also known as
PLGF-2 (4-9) and PGF-3, also known as PLGF-3 (5,8).
However, only one study has described a fourth isoform,
PLGF-4 in human trophoblast and endothelial cells (4).
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PGFs mediate their effects through VEGFR-1. PGF-2 has
a 21-amino acid heparin binding domain and is also able to
bind both of the known PGF receptors: neuropilin-1 (Nrp-1)
and FLT-1 while PLGF-1 and PGF-3, both lack the heparin
binding domain, and bind only FLT-1.
Nrp-1 is a 120-130 kDa membrane glycoprotein, first
identified as a neuronal receptor for specific secreted members
of semaphorin family involved in axon repulsion. The extra-
cellular region consists of three domains: the a1/a2 domain,
which is homologous to the complement-binding motifs; the
b1/b2 domain, which is homologous to coagulation factors V
and VIII; and the c domain, which is homologous to meprin,
A5 and receptor tyrosine phosphatise μ and is designated
MAM (10).
Several studies on VEGF and PGF have revealed that they
exert similar biological functions in stimulating the growth of
vascular endothelial cells (6). PGF promotes motility and
invasiveness, two main features associated with the epithelial
to mesenchymal transformation that characterizes metastasis
(9). In vitro results available on the angiogenesis role of PGF
are inconsistent, some studies have revealed that PGF binding
to VEGFR-1 (FLT-1) did not produce any growth or
angiogenesis in endothelial cells (ECs), while others show
that PGF/VEGFR-1 signalling promotes EC viability and
angiogenesis. It seems clear thought that in placenta, PGF
has a direct effect on endothelial cells, by enhancing its own
signalling and by amplifying VEGF-driven angiogenesis (5).
Breast cancer is the most common form of malignancies in
females in the UK and metastastasis of breast cancer is
common. About 7% of patients with breast cancer present with
widespread metastases at the initial presentation. The most
common sites of metastasis are bone, lungs, liver, chest and
the central nervous system. The role of VEGF in breast cancer
has been well documented. However, the role of PGF
isoforms and the PGF receptor neuropilin is not established.
We have previously reported that transcript levels of PLGF
are raised in aggressive breast tumours (11). To clarify the
role of PLGF-1 and PGF-2 and its receptor, neuropilin, in
breast cancer and its prognostic significance, we examined
the expression of both isoforms and how changes in
expression may be linked to prognosis of the disease, through
analyses of the transcripts and proteins of these molecules, in
a cohort of human breast cancer specimens.
Materials and methods
Human breast specimens. A total of 144 breast samples were
obtained from breast cancer patients (30 background normal
breast tissue and 114 breast cancer tissue), with consent of the
patients and the Ethics Committee. These tissues were
collected immediately after mastectomies and snap-frozen in
liquid nitrogen. The pathologist (A.D.J.) verified normal
background and cancer specimens and it was confirmed that
the background samples were free from tumour deposit.
Polymerase chain reaction (PCR). Human breast cancer tissue
was screened for endogenous expression of PLGF-1 and
PGF-2.
Conventional PCR was performed using cDNA together
with PCR master mix using respective primers. PLGF-1 and
PGF-2 forward and reverse primers were 5'-ATGCCGGTCA
TGAGGCTGTTCCCTTGCTT-3' and 5'-TTACCTCCGGG
GAACAGCATCGCCGCAC-3', two products being distin-
guished by their charactistic size differences. The reaction
conditions were: 94˚C for 5 min, 94˚C for 15 sec, 61˚C for
30 sec, 72˚C for 1 min and the final extension phase at 72˚C
for 10 min for 42 cycles. The PCR products were separated on
a 1.4% agarose gel and electrophoretically separated. The gel
was then stained with ethidium bromide prior to examination
under ultraviolet light, and photographs were taken.
Real-time quantitative polymerase chain reaction (Q-PCR).
The Q-PCR used was the Amplifluor™ Uniprimer™ system
(Intergen Company Oxford, UK) and the Thermo-Start®
(ABgene, Epsom, Surrey, UK), as previously reported
(12,13). Specific primers were designed by the authors using
Beacon Designers software (Biosoft, Palo Alto, CA, USA)
and manufacturated by Invitrogen (Invitrogen Life
Technologies, Paisley, UK). Using the Icycler IQ system
(Bio-Rad, Hemel Hempstead, UK), which incorporates a
gradient thermocycler and a 96-channel optical unit, the
breast samples cDNA were simultaneously assayed with a
purified plasmids as internal standard. The level of each
molecule cDNA (copies/50 ng RNA) in the breast samples
was calculated. Q-PCR for ß-actin was also performed on the
same samples, to correct for any residual differences in the
initial level of RNA in the specimens (in addition to spectro-
photometry). Primer pairs for Q-PCR were as follows:
PLGF-1 forward and reverse primers were 5'-GTTCTCTCA
GCACGTTCG-3' and 5'-ACTGAACCTGACCGTACACAT
CGCCGCACCTTTC-3' and PGF-2 forward and reverse
primers were 5'-GGAGCTGACGTTCTCTCAG-3' and 5'-ACT
GAACCTGACCGTACAGTTACCTCCGGGGAACAG-3'.
Primers for neuropilin-1 forward and reverse were 5'-TCAA
CTTCAACCCTCACTTC-3' and 5'-AACTTTCCCCTAAA
ATGTCC-3'.
Immunohistochemical staining of breast specimens and
densitometry analysis. This was based on methods we
previously described (14-16). Frozen sections of breast
tumour and back-ground tissue were cut at a thickness of 6 μm
using a cryostat (Leica). The sections were mounted on super
frost microscope slides, air-dried and then fixed in a mixture
of 50% acetone and 50% methanol. The sections were then
placed in Optimax wash buffer (Menerium, Oxford, UK) for
5-10 min to rehydrate. Sections were incubated for 20 min in a
horse serum albumin blocking solution and probed with
PLGF-1, PGF-2 and neuropilin-1 antibody (1:100 dilution),
and without primary antibody as a negative control to verify
the binding specificity. Primary antibodies were purchased
from Santa Cruz Biotechnologies Inc. (Santa Cruz, CA, USA).
Following extensive washings, sections were incubated with
the secondary biotinylated antibody and biotinylation
solution, separated by extensive washings. Diaminobenzine
chromogen (ABC Standard kit, Vector Laboratories,
Peterborough, UK) was then added to the sections and
incubated in the dark for 5 min. Sections were counter-
stained in Gill's haematoxylin and dehydrated in ascending
grades of methanol before clearing in xylene and mounting
under a cover slip. Semi-quantification of staining intensity
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was carried out using Optimas package as we previously
described (13). Immunohistochemical photographs of normal
and tumour sections (n=20) were assessed as previously
described (15).
Statistical analysis. Statistical analyses were carried out using
paired samples Student's t-test (mean ± SD), Fisher's test
(two-tailed) and by the non-parametric Mann-Whitney test
(IQR) where appropriate. A P-value ≤0.05 was defined as
statistically significant. Fisher's exact tests were used for
analysing neuropilin, the transcript of which was below
detection in a good proportion of the tissues. Statistic tests
were performed using SPSS 10.0 software (SPSS Inc.,
Chicago, IL, USA).
Results
Expression of PLGF-1 and PGF-2 in breast cancer tissue.
PLGF-1 and PGF-2 transcripts were detected in breast cancer
tissue and were seen as two discrete products, 447 and 512 bp
in size, respectively, Fig. 1.
Immunohistochemical staining of breast specimens. Breast
cancer tissue stained positively for PLGF-1, PGF-2 and
neuropilin-1. The PLGF-1 and PGF-2 protein level was
dramatically elevated in the breast tumour specimens
compared with the normal breast tissue (Fig. 2). Staining
intensity of PLGF-1 and PGF-2 in tumour tissues were
significantly higher than in the normal breast tissue (mean ± SD
131±53.40 vs. 103.105±22.09, P=0.031949, 172.82±40.33
vs. 102.05±46.65 P=0.000117, for PlGF-1 and PGF-2,
respectively.
In neuropilin-1, the pattern of staining correlates with the
staining for PGF-2 in breast cancer tissue compared with
normal breast tissue (Fig. 3).
Quantification of PLGF-1 and PGF-2 transcripts in human
breast tissues. We quantified the PLGF-1 and PGF-2 trans-
cripts in the breast specimens (tumour n=114, background
n=30) using real-time Q-PCR (all values are displayed as
mean transcript copies). We show that the PLGF-1 expression
value in normal breast tissue was 182±107, compared with
77±24 in the breast cancer tissue (Fig. 4A), however, this did
not reach a level of significance (P=0.34).
PGF-2, expression value in cancer tissue was 1548±291,
compared with normal breast tissue 984±125. Levels of
PGF-2 were higher in cancer tissue, although this did not
reach a level of significance (P=0.077).
PGF-2 was sequentially increased with increasing
Nottingham Prognostic Index (NPI), (Fig. 4C), status from
940±89.7 in NPI 1 (NPI <3.5) tumours to 2913±1699 in
NPI 3 tumours (NPI >5.4). PLGF-1 was increased in NPI 2
(NPI 3.5-5.4) tumours (124.2±76.4 vs. 52.5±13.6 in NPI 1)
but showed a little change in NPI 3 tumours (61.7±16.5).
However, these changes did not reach significance
(P=0.67).
When expression was compared with tumour grade,
PLGF-1 showed no obvious correlation (grade 1, 192±143;
grade 2, 124.2±76.4; grade 3, 61.7±16.5).
PGF-2 expression was increased in grade 3 when compared
to grade 1 (grade 1 1773±623 vs. 4545±3677) although this
did not reach significance (P=0.49).
PLGF-1 and PGF-2 and estrogen receptor status. No
significant correlation was seen between PLGF-1, PGF-2 and
ER status. PLGF-1 and PGF-2 expression appears to
correlate with estrogen-receptor ß (ERß) grouping (ERß-
positive n=75 and ERß-negative n=22). Levels of both PLGF-1
and PGF-2 were found to be significantly elevated in ERß-
negative patients (P=0.014 for PLGF-1 and P=0.0004 for
PLGF-2) reaching statistical significance (Fig. 5).
PLGF-1 and PGF-2 and nodal status. PLGF-1 and PGF-2 in
the node-positive tumours (n=47) were elevated compared with
node-negative patients (n=54) (52.5±14 vs. 104±52; P=0.34
for PLGF-1 and 941±90 vs. 2231±632; P=0.049 for PGF-2),
(Fig. 4B).
PLGF-1 and PGF-2 and survival status. We assessed the
survival status of the breast cancer patient in association with
PLGF-1 and PGF-2 levels, with a period of 10 years median.
Patients were classified as 1) disease-free, 2) with metastatic
disease, 3) with local recurrence of breast cancer, and 4) dead
as a result of breast cancer.
Patients who had died of breast cancer had a significantly
elevated levels of PLGF-1 (P=0.03), (Fig. 6). However, the
same was not seen with PGF-2 (P=0.7857).
Expression of neuropilin-1 receptor. Neuropilin-1 transcript
expression in the breast specimens was examined using real-
time Q-PCR. There were a substantial number of samples in
which neuropilin transcript was below detections. Samples
were subsequently separated into two groups. Those where
the neuropilin-1 receptor transcript was detectable (positive)
and those where the receptor was below detection (negative).
The difference between the neuropilin-1 receptor status and
their correlation with a number of other important factors in
breast cancer were analysed using a two-tailed Fisher's test
and were regarded as significant at P<0.05, Table I. A
significantly higher portion of patients classified as having a
poor prognosis (Nottingham Prognostic Index, NPI, >5.4)
were found to be receptor-positive compared to those
classified with a good NPI (<3.4) status (P=0.033).
When looking at tumour grade of differentiation, we found
that those patients classified with a low grade tumour (Grade 1)
were significantly more likely to be negative for the detection
of neuropilin-1 when compared to patient samples with higher
grade classification (Grade 3) (P=0.008).
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Figure 1. PCR analyses of PLGF-1 and PGF-2 isoform expresses by breast
cancer tissue samples. A DNA ladder was included for size approximation.
PLGF-1 is reported to be 447 base pair while PGF-2 is 512 base pair.
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Similarly, samples obtained from patients with a good
clinical outcome (disease-free) were found to be significantly
more likely to be neuropilin-1-negative than those from
patients who had died as a result of the disease (P<0.001).
A correlation between ERß status and neuropilin-1 status
was also observed. Patients who were ERß-positive were also
found to be mainly neuropilin-1-negative when compared to
those patients who were ERß-negative (P=0.042).
Discussion
PGF is a member of the VEGF family and is known to be a
powerful angiogenic factor. VEGF has arisen as a pivotal
regulator of the angiogenic process in physiological and
pathological conditions as in various human malignancies,
including breast cancer. Although PGF has been studied in a
number of clinical tumour types, little is known about the
different isoforms, PLGF-1, PGF-2, PGF-3 and their prognostic
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Figure 2. Immunohistochemical staining for PLGF-1 and PGF-2 of human breast specimens. (A and B) Strong cytoplasmic staining of PLGF-1 in human breast
cancer tissue. (C and D) Negative staining in normal background breast tissue for PLGF-1. (E and F) Strong cytoplasmatic staining for PGF-2 in human cancer
tissue, (G and H) negative staining in normal background breast tissue for PGF-2. These sections demonstrate that both PLGF-1 and PGF-2 are expressed at far
higher levels in the breast tumour specimens compared with the normal breast tissue (original magnification x100).
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significance in human breast cancer. The current study
evaluated these factors in relation with PLGF-1 and PGF-2 and
the PGF receptor neuropilin. We investigated the expression
of PLGF-1 and PGF-2, at the protein level and the messenger
RNA level and whether it has a significant value in the
prognosis of the breast cancer patients. To the best of our
knowledge this study is the first reporting that both isoforms
were detected in all breast cancer tissues and the matched
normal tissues, however, only limited reports have studied
mRNA expression of PGF irrespective of the isoform.
High levels of PGF-2 mRNA were found in breast tumour
tissues, this correlated with the IHC staining intensity, whereas
PLGF-1 showed a higher expression in normal tissue although
not statistically significant. This result does not correlate with
the IHC for this isoform. This may be due to the non-
discriminative nature of Q-PCR. We cannot determine which
cells exclusively express PLGF-1. In IHC, we can observe
where the higher staining intensity is, relative to weak
staining. Moreover, IHC is a semi-quantitative method. We
confirm that PLGF-1 and PGF-2 mRNA levels were
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Figure 3. Immunohistochemical staining for neuropilin-1 of human breast specimens. (A-D) Negative staining in normal background breast tissue for
neuropilin-1. (E-H) A good level of neuropilin-1 in human breast cancer tissue, the staining tends to be cytoplasmatic. The pattern of staining of neuropilin-1
correlates with the staining of PGF-2, which shows a markedly increased staining in human breast cancer tissue compared to normal background breast tissue.
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dramatically elevated when looking at clinical outcome for
these patients. Levels of PLGF-1 and PGF-2 were higher in
tumour tissues from patients who died from breast cancer
compared with those who survived. In keeping with this trend,
patients who died from breast cancer were also found to have
a higher proportion of the receptor for PLGF-1 and PGF-2,
neuropilin-1. This high degree of expression of PLGF-1 and
PGF-2 together with the presence of neuropilin-1 was
indicative for a poor prognosis for patient. Therefore, both
isoforms demonstrate strong prognostic potential.
The Nottingham prognostic index (NPI), has been used as
a prognostic indicator, with its reliability being validated in
several studies (17). Both, PLGF-1 and PGF-2 showed a
high expression at NPI-2 and NPI-3, correlating these
results with the poor prognosis we described before.
Similarly, the proportion of patients having positive readings
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Figure 4. Levels of transcript of PLGF-1 and PGF-2. (A) PlGF1 (A1) and PGF-2 (A2) in tumour samples in comparison to background. (B) Levels of
transcript of PLGF-1 (B1) and PGF-2 (B2) expression in node-positive tumours compared with node-negative tumours. (C) Levels of PLGF-1 (C1) and PGF-2
(C2) transcripts in correlation with the Nottingham Prognostic Index (NPI).
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for neuropilin-1 was also found to increase in conjunction
with the increase in NPI indices, becoming significantly
increased in patients with NPI >5.4 compared to with NPI
<3.4. Our results for PLGF-1 and PGF-2 levels are increased
in node-positive tumours, demonstrating the association of
high levels of both isoforms with a poor prognosis in the
patients.
The findings on neuropilin-1 are interesting, as it was only
recently that this receptor was tested in clinical breast
cancer. Similar to the findings in the present study, Ghosh
et al (18) has shown that highly levels of neuropilin-1 is
associated with a poor prognosis in patients with breast
cancer. This, together with studies that peptides targeting
certain regions of neuropilin results in the death of breast
cancer cells which express neuropilin Barr (19), strongly
indicate that targeting neuropilin-1 may have potential in
new anti-cancer therapies. The correlation between PLGF-1,
PGF-2 and neuropilin with ERß status is interesting. While
PLGF-1 and PGF-2 were present at higher levels in ERß-
negative tumours, neuropilin-1 results were the opposite. The
mutual impact of PLGF-1/PGF-2 and ERß in breast is yet to
be tested, but may prove to be an interesting lead to pursue,
given the complex and uncertain nature of ERß in cell
functions.
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Figure 5. Levels of transcript of PLGF-1 and PGF-2 expression in node-
positive tumours compared with node-negative tumours.
Figure 6. Comparison of transcript levels of PLGF-1 (top) and PGF-2 (bottom)
in correlation with clinical outcome.
Table I. Results for neuropilin-1 expression in the patient
cohort.a
–––––––––––––––––––––––––––––––––––––––––––––––––
Neuropilin-1
––––––––––––––– P-value
Groups Negative Positive (Fisher's test, two-tailed)
–––––––––––––––––––––––––––––––––––––––––––––––––
NPI level
Good 45 9
Moderate 28 4 P=0.759 (vs. good)
Poor 8 7 P=0.033 (vs. good)
Grade of
differentiation
Grade 1 17 0
Grade 2 29 6
Grade 3 38 16 P=0.008 (vs. Grade 1)
Survival status
Disease-free 57 16
Metastatic disease 6 0 P=0.34 (vs. disease-free)
Dead 2 13 P<0.001 (vs. disease-free)
Estrogen
Receptor ß
Negative 46 17
Positive 30 3 P=0.042
–––––––––––––––––––––––––––––––––––––––––––––––––
aData were obtained by scoring (high/low) RNA levels derived from
Q-PCR data. The actual relative levels were too low for conventional
analysis.
–––––––––––––––––––––––––––––––––––––––––––––––––
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In summary, this study has shown that PLGF-1 and PGF-2
expression of the angiogenic factor, PGF, are increased in
breast tumour tissues compared with normal breast tissues and
together with the PGF receptor, neuropilin, display prognostic
value in breast cancer patients. This indicates that blocking/
targeting PLGF-1 and PGF-2 expression may have a promising
therapeutic future in breast cancer.
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